Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice-Reference-Cited by-同舟云学术

Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptor‐positive breast cancer: implications for clinical practice

Published:2021-05-03 Issue:1 Volume:79 Page:47-56
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Badr Nahla M¹²^ORCID,Spooner David³,Steven Jane³,Stevens Andrea³,Shaaban Abeer M¹³^ORCID

Affiliation:

1. Institute of Cancer and Genomic Sciences The University of Birmingham Edgbaston Birmingham UK

2. Department of Pathology Faculty of Medicine Menoufia University Shebin El‐Kom Egypt

3. Queen Elizabeth Hospital BirminghamUniversity Hospitals Birmingham NHS Foundation Trust Birmingham UK

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.14331

Reference39 articles.

1. Neoadjuvant endocrine treatment in primary breast cancer – Review of literature

2. Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives

3. Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

4. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

5. Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers;International Journal of Molecular Sciences;2024-07-05

2. Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study;Histopathology;2024-06-07

3. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models;British Journal of Cancer;2024-04-10

4. Practical approach to diagnosis of breast lesions with heterologous components;Diagnostic Histopathology;2024-02

5. The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy;Annals of Surgical Oncology;2023-07-15